title: Rituximab therapy for Wegener's granulomatosis refractory to conventional treatment.
authors: A
authors: A
authors: Sánchez-Escuredo
authors: R
authors: R
authors: Núñez
authors: M
authors: M
authors: Ibernón
authors: E
authors: E
authors: Martínez
authors: D
authors: D
authors: López
authors: M
authors: M
authors: Navarro
authors: J
authors: J
authors: Bonet
authors: J
authors: J
authors: Ara
authors: R
authors: R
authors: Romero
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology*; D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood / Q000276:immunology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001324:Autoantigens / Q000276:immunology; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004198:Disease Susceptibility; D004351:Drug Resistance; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006469:Hemoptysis / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D053146:Myeloblastin / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000209:etiology*; D012008:Recurrence; D000069283:Rituximab
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D001324:Autoantigens; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D053146:Myeloblastin; D009173:Mycophenolic Acid; D011241:Prednisone; D008775:Methylprednisolone